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Abstract
Gastric cancer (GC) is one of the leading causes of 
cancer related death in the world, particularly in East 
Asia. According to the Correa’s cancer cascade, non-
cardia GC is usually developed through a series of 
mucosal changes from non-atrophic gastritis to atrophic 
gastritis (AG), intestinal metaplasia (IM), dysplasia 
and adenocarcinoma. Atrophic gastritis and IM are 
therefore generally considered to be pre-neoplastic 
gastric lesions. Helicobacter pylori  (H. pylori ) infection 
is an important initiating and promoting step of this 
gastric carcinogenesis cascade. Emerging long-term 
data showed that eradication of H. pylori  reduced the 
risk of subsequent cancer development. It however 
remains confusing whether eradication of the bacterium 
in individuals with pre-neoplastic gastric lesions could 
regress these changes as well as in preventing cancer. 
Whilst H. pylori  eradication could likely regress AG, 
the presence of IM may be a point of no return in 
this cascade. Hence, surveillance by endoscopy may 
be indicated in those with extensive IM or those with 
incomplete IM, particularly in populations with high 
GC risk. The optimal interval and the best tool of 
surveillance endoscopy remains to be determined in 
future studies.
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Core tip: Gastric intestinal metaplasia (IM) is generally 
considered to be a pre-neoplastic gastric lesion, which 
is usually triggered by chronic Helicobacter pylori  
(H. pylori ) infection. However, the role of H. pylori  
eradication in treating gastric IM remains controversial. 
It remains uncertain whether the presence of gastric IM 
signifies an irreversible step of histological progression. 
Despite the definite increase in risk of gastric cancer 
development, the role of endoscopic surveillance 
remains dubious. This review will summarize the latest 
literature on treatment and surveillance of gastric IM. 
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INTRODUCTION
Gastric cancer (GC) is one of the most common 
cancers in the world and is the third leading cause 
of cancer mortality[1]. Although the incidence of GC 
is declining worldwide, the number of new cases is 
still rising due to population growth and the aging 
population[2]. In particular, the burden of the disease 
remains high in East Asian countries. In 2012, almost 
one million new gastric cancers were diagnosed in 
the world and half of them occurred in East Asia[3]. 
Since early cancers are usually asymptomatic, two-
thirds of the patients presented at an advanced stage 
when curative resection was not possible. Despite 
the advances in treatment, the prognosis of patients 
with advanced gastric cancer remained dismal with a 
median survival of less than 1 year[4].
The development of GC is generally believed to 
be a multistep process involving sequential changes 
of the gastric mucosa from non-atrophic gastritis to 
atrophic gastritis (AG), intestinal metaplasia (IM), 
dysplasia and finally carcinoma[5]. The process is 
thought to be initiated and promoted by Helicobacter 
pylori (H. pylori) and as a result, this bacterium 
has been classified by the International Agency for 
Research on Cancer of the World Health Organization 
as a class Ⅰ carcinogen[6]. In a recent meta-analysis, 
the relative risk (RR) of developing non-cardia GC in H. 
pylori infected patients was 2.8[7]. 
Intuitively, eradication of H. pylori may halt the 
progression of the gastric carcinogenesis cascade and 
therefore reduce the risk of developing GC. Indirect 
evidence from populations with very low prevalence of 
H. pylori, such as Malays in the northeastern region of 
Malaysia, also support a decreased risk in developing 
pre-neoplastic lesions and GC in those populations[8]. 
However, previous studies that examined the role 
of H. pylori eradication in preventing GC yielded 
conflicting results, which may be accounted by the 
heterogeneity in sample size, ethnicity of study 
population and follow up duration. It remains even 
more controversial whether the presence of gastric IM 
is the point of no return in this gastric carcinogenesis 
cascade. This review examines the latest evidences on 
the prevention and treatment of H. pylori gastric pre-
neoplastic conditions, as well as the role of surveillance 
of these lesions.
H. pylori eRaDICaTION IN pReveNTION 
Of gasTRIC CaNCeR IN INDIvIDUals 
wITh baselINe pRe-NeOplasTIC 
lesIONs
Due to the long lag time between H. pylori infection 
and cancer development, clinical trials design to 
investigate the effects of H. pylori eradication in 
preventing GC development are complicated. These 
trials will require not only prolonged follow-up 
duration but also large sample size to be conducted 
in high-risk populations. Several randomized trials 
have been conducted in the past and the results are 
summarized in a recent meta-analysis, which showed 
that eradication of H. pylori resulted in 34% reduction 
in the incidence of GC[9]. However, the benefits may 
be more prominent in Asian patients where GC is 
more prevalent, particularly in Chinese men whom the 
number needed to treat was as low as 15.
Despite the potential benefits of H. pylori 
eradication in preventing GC, it remains more con-
troversial whether the presence of pre-neoplastic 
lesions will preclude the benefits of eradication in 
cancer prevention. In the subgroup analysis of a 
randomized trial of H. pylori eradication in preventing 
gastric cancer in China[10], Wong et al[10] showed 
that the potential benefits of H. pylori eradication 
in preventing GC was limited to patients without 
precancerous lesions at baseline. In a recent meta-
analysis, Chen et al[11] looked at the baseline 
histological changes and the risk of GC after H. pylori 
eradication. They found that although the risk of GC 
was lowered in the anti-H. pylori treatment group 
(RR = 0.64, 95%CI: 0.48-0.85), subgroup analysis 
in patients with existing IM and dysplasia could not 
confirm the potential benefits (RR = 0.88, 95%CI: 
0.59-1.31). H. pylori eradication also had no effect 
on regression of these lesions (RR = 0.81, 95%CI: 
0.64-1.03). Hence, the presence of IM was believed 
to be a “point of no return” in the cancer cascade 
of GC where treatment of H. pylori appears to be of 
no benefit. Nonetheless, in a more recent subgroup 
analysis of the 15-year effects of H. pylori treatment 
on gastric cancer incidence and mortality, Li et al[12] 
demonstrated that treatment was still associated with 
a significant reduction in gastric cancer incidence even 
in patients with baseline IM and dysplasia.
Based on the latest evidence, H. pylori treatment 
should still be recommended to individuals with existing 
pre-neoplastic lesions with the hope of reducing the 
risk of GC. The recent revised guidelines from Eastern 
countries (China, Japan and Korea) and Europe 
(Maastricht Ⅳ Consensus report) all support H. pylori 
eradication to reduce the risk of gastric cancer[13-16]. 
Recommended H. pylori eradication regimen differed 
slightly in each region because of the difference in 
local antibiotic resistance profile. Table 1 summarized 
the recommended first and second line H. pylori 
eradication regimen from each region. Unfortunately, 
due to the rising clarithromycin resistance[17], the 
eradication rate of clarithromycin containing triple 
therapy is declining globally, sometimes to an 
unacceptable eradication rate of less than 80%[18]. 
Several new H. pylori eradication regimens, including 
sequential therapy and concomitant therapy of three 
antibiotics given over a period of 10-14 d, have been 
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developed to overcome the problem of antimicrobial 
resistance. 
gasTRIC pRe-NeOplasTIC lesIONs 
aND RIsk Of gC
Whilst gastritis is seen in virtually all H. pylori infected 
subjects, only around 10% of the infected individuals 
with chronic active gastritis progressed to severe 
AG[19]. Since this progression is related to chronic 
inflammation of the gastric mucosa, there is a strong 
age-associated increase in the prevalence of IM as 
well[20]. Male gender and those with first-degree family 
history of GC have been shown to have an increase 
in risk of developing IM[21]. We have also shown that 
presence of certain H. pylori genotype (vacA m1) and 
polymorphisms of the host inflammatory cytokines 
(interleukin-1β) were associated with the presence 
of gastric IM in Chinese population[22]. In the meta-
analysis by Marques-Silva et al[23], it was also shown 
that there were wide geographic variations of AG and 
IM. The prevalence of AG in the worldwide population 
in general was 33.4% and increased to 42% in 
countries with high incidence of GC. The prevalence 
of IM in the worldwide population was 25% whereas 
extensive IM was found in 13%. In low-prevalence 
western cohort, the annual incidence of progression 
to GC is 0.1% for AG, 0.25% for IM and 0.6% for 
mild to moderate dysplasia[24]. The rate of progression 
however appears to be higher in Asian population. In 
a Japanese study, Uemura et al[25] showed that the 
RR of progression to cancer was 1.7, 4.9 and 6.4 in 
patients with moderate atrophy, severe atrophy and 
IM, respectively.
Histologically, IM can be further classified into 
complete or incomplete as originally proposed 
by Matsukura et al[26], which depends on the pre-
sence of small intestinal digestive enzymes. It is 
currently separated into complete or incomplete 
by the resemblance of small intestinal or colonic 
epithelium, respectively[27]. Another classification 
was developed by Jass and Flipe[28], which further 
classified incomplete IM into type Ⅱ or Ⅲ by the 
mucin expressions. Type Ⅰ, or complete IM, expresses 
only sialomucins and type Ⅲ expresses sulfomucins. 
Type Ⅱ is a hybrid form which expresses a mixture 
of gastric and intestinal mucins. These subtyping 
would require the use of combined high-iron dia-
mine and alcian blue staining which is not widely 
available in routine service laboratory. It also remains 
undetermined whether there are sequential changes 
from type Ⅰ to type Ⅲ, and simultaneous expression 
of different types of mucins are not infrequent[27]. In 
a recent review by González et al[29], the prevalence 
of type Ⅲ IM were significantly higher in GC in 13 of 
14 cross-sectional studies and there was a significant 
association of type Ⅲ or incomplete IM with GC in 6 of 
10 follow-up studies.
Apart from the IM subtypes, the extent of IM is also 
crucial in determining the subsequent risk of GC. In 
general, lesions along the lesser curve from the cardia 
to pylorus [odds ratio (OR) of 5.7] and with diffuse 
pattern involving essentially the entire gastric mucosa 
(OR of 12.2) are at higher risk of GC[30]. To this end, 
the operative link assessment of gastritis assessment 
(OLGA) staging system was proposed to stage the 
severity and extent of AG into stages 0 to Ⅳ (Table 
2)[31]. This staging system was shown to be very useful 
in predicting the risk of GC development, particularly 
in patients with stage Ⅲ-Ⅳ AG. While the unequivocal 
diagnosis of AG is sometimes difficult and IM is more 
easily recognizable histologically, a modification to 
the OLGA to the new staging system of operative link 
for gastric intestinal metaplasia assessment (OLGIM) 
by replacing AG with IM system was proposed[32]. 
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Table 1  Recommended first and second line Helicobacter pylori  eradication regimen
1st line regimen 2nd line regimen
Japan[15] PPI, amoxicillin 750 mg, clarithromycin 200 mg to 400 mg twice daily PPI, amoxicillin 750 mg, metronidazole 250 mg twice daily
Duration: 7 d Duration: 7 d
Korea[14] PPI, amoxicillin 1 g, clarithromycin 500 mg twice daily PPI, bismuth 120 mg four times daily, tetracycline 500 mg four times 
daily, metronidazole 500 mg three times daily
Duration: 7-14 d Duration: 7-14 d
Europe[16] PPI-clarithromycin containing triple therapy OR Bismuth-containing quadruple therapy OR levofloxacin-containing 
triple
Bismuth or non-bismuth containing quadruple1
Duration: 7-14 d Duration: 10 d
China[13] No preferential choice. Options include: 
(1)PPI, amoxicillin 1 g, clarithromycin 500 mg twice daily
(2) PPI, amoxicillin 1 g, levofloxacin 200 mg twice daily (or levofloxacin 500 mg daily)
(3) PPI, amoxicillin 1 g, furazolidone 100 mg twice daily
(4) PPI, tetracycline 750 mg, metronidazole 400 mg twice daily (or metronidazole 400 mg three times per day)
(5) PPI, bismuth 220 mg plus any of the two antibiotics above twice daily
Duration: 7-14 d
1Bismuth quadruple or non-bismuth quadruple (sequential or concomitant) as the preferred choice in regions with high clarithromycin resistance profile (> 
20%). Choice of PPI includes lansoprazole 30 mg, omeprazole 20 mg, rabeprazole 20 mg, esomeprazole 20 mg, or pantoprazole 40 mg. PPI: Proton pump 
inhibitor.
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have been used for treatment of gastric pre-neoplastic 
lesions including anti-oxidants and cyclooxygenase-2 
(COX-2) inhibitor. COX-2 is an enzyme responsible for 
the conversion of arachidonic acid to prostaglandins. 
It has been shown to be overexpressed and involved 
in gastric IM and cancer[41]. Whilst COX-2 selective 
inhibitors have been shown to reduce the risk of 
various cancers including colon and breast cancer, 
the role of COX-2 inhibitors have been tested in two 
randomized controlled trial in Chinese patients[42,43]. 
In our previous randomized controlled study, patients 
with gastric IM after eradication of H. pylori were 
allocated to receive rofecoxib or placebo for 24 mo. 
There was no significant difference in the percentage 
of patients with regression or complete resolution of 
IM after rofecoxib treatment. In another randomized 
trial by Wong et al[43] patients with H. pylori infection 
and advanced gastric lesions including severe chronic 
AG, IM and dysplasia were assigned to receive 
different treatment options including eradication of H. 
pylori, a 2-year course of celecoxib, combination of 
both or placebo[44]. They found that when compared 
to placebo, the proportions of patients with regression 
of gastric lesions were significantly increased in the 
celecoxib group and the H. pylori treatment group. 
There was however no significant effect in the group 
who received both anti-Helicobacter therapy and 
celecoxib. More importantly, 9 patients developed 
early gastric cancer in this study and all except one 
have indefinite dysplasia or dysplasia at baseline. The 
remaining patient had baseline deep IM. Together, 
these data do not suggest an additional benefit of 
COX-2 inhibitor over treatment of H. pylori alone in 
preventing the progression of gastric IM (Table 3). 
Vitamins and other anti-oxidants have also 
been tested in the treatment of gastric precancerous 
lesions in a randomized trial in China[44]. Subjects 
were randomly assigned in a factorial design to 
receive anti-Helicobacter therapy; vitamin C, vitamin 
E, and selenium (vitamin supplement); or an aged 
garlic extract and steam-distilled garlic oil (garlic 
supplement). Although H. pylori eradication significantly 
reduced the combined prevalence of chronic AG, IM, 
dysplasia or cancer, vitamin or garlic supplement had 
no effect on gastric precancerous lesions. Hence, there 
is so far no compelling evidence to support the routine 
use of vitamins or anti-oxidants.
Smoking and high salt diet have also been linked to 
the development of gastric pre-neoplastic lesions[45,46]. 
Although the OLGIM was found to provide a better 
inter-observer agreement than OLGA, a significant 
proportion of patients with stage Ⅲ-Ⅳ OLGA were 
missed if only the OLGIM was applied[33]. In high GC 
risk population such as Korea, it was found that old 
age, smoking and H. pylori infection were associated 
with high risk OLGA and OLGIM stages[33]. High-risk 
OLGIM stages were infrequent before the age of 40 
(2.8%) but increased to 30.1% for those in the 60s.
H. pylori eRaDICaTION aND ChaNges 
Of gasTRIC pRe-NeOplasTIC lesIONs
While eradication of H. pylori could restore the 
gastric mucosa to normal in individuals with H. pylori 
associated chronic gastritis alone[34,35], the role of H. 
pylori treatment in reversing gastric pre-neoplastic 
changes remain less certain[36]. The presence of IM in 
the stomach is usually associated with a lower level 
of H. pylori colonization due to the change in gastric 
mucus and acidity. Hence, the potential therapeutic 
effect of H. pylori eradication may be minimal. In 
our previous randomized controlled trial in Chinese 
population, we found that progression of IM was 
more often in those with persistent H. pylori infection, 
male subjects and those aged more than 45 years[37]. 
However, eradication of H. pylori alone did not prevent 
progression in all patients, particularly in those with 
more extensive and severe IM at baseline. In a meta-
analysis that included 16 studies[38], the investigators 
found that there was significant improvement of 
AG in the gastric antrum and the gastric corpus 
after treatment for H. pylori. As for IM, significant 
improvements were only seen in the antrum but not 
in the corpus. Yet, two previous meta-analyses did not 
find any improvement in IM regardless of the location 
of the lesions[39,40]. 
Further long-term follow up studies are therefore 
necessary to determine whether H. pylori eradication 
could regress gastric IM, particularly those in the 
corpus. Studies are also needed to address whether 
there are any changes in gastric IM subtypes after 
treatment against H. pylori. 
OTheR TReaTmeNTs fOR gasTRIC 
pRe-NeOplasTIC lesIONs
Apart from treatment against H. pylori, other agents 
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Table 2  Operative Link for Gastritis Assessment[31]
Corpus
No atrophy (score 0) Mild atrophy (score 1) Moderate atrophy (score 2) Severe atrophy (score 3)
Antrum (including incisura angularis)
No atrophy (score 0) Stage 0 Stage Ⅰ Stage Ⅱ Stage Ⅱ
Mild atrophy (score 1) Stage Ⅰ Stage Ⅰ Stage Ⅱ Stage Ⅲ
Moderate atrophy (score 2) Stage Ⅱ Stage Ⅱ Stage Ⅲ Stage Ⅳ
Severe atrophy (score 3) Stage Ⅲ Stage Ⅲ Stage Ⅳ Stage Ⅳ
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As yet, there is no clinical trial to look into the role of 
smoking cessation or diet manipulation on changes of 
gastric pre-neoplastic lesions. 
Whilst gastric dysplasia can also be treated 
by endoscopic resection like endoscopic mucosal 
resection or endoscopic submucosal dissection, the 
role of endoscopic treatment for gastric IM is not 
defined. With the high success of eradicating IM in the 
esophagus in patients with Barrett’s esophagus[47], 
we have recently examined the role of endoscopic 
radiofrequency ablation (RFA) for gastric IM and 
dysplasia[48]. Although endoscopic RFA could ablate 
gastric low-grade dysplasia, gastric RFA failed to 
completely ablate gastric IM. Hence, endoscopic 
treatment may not be indicated in these patients with 
gastric IM only.
sURveIllaNCe Of pRe-NeOplasTIC 
CONDITIONs
Despite the risk of progression of gastric pre-neoplastic 
lesions, there is so far no definitive evidence to support 
the routine surveillance of gastric IM. In a recent 
Cochrane systemic review of surveillance of gastric 
IM in the prevention of GC[49], no studies met the 
inclusion criteria including randomization and a proper 
comparative group. Hence, there is a genuine need for 
properly conducted clinical trials to address this issue. 
On the other hand, there are several western 
guidelines published on the recommendation for 
surveillance of gastric IM. Due to the low risk of 
gastric cancer in the United States, the American 
Society for Gastrointestinal Endoscopy does not 
uniformly recommend surveillance for gastric IM[50]. 
However, endoscopic surveillance with topographic 
mapping of the entire stomach in subjects at 
increased risk of gastric cancer on the basis of ethnic 
background, immigration from a geographic location 
with high gastric cancer risk, or family history is 
recommended. There is also no recommendation on 
surveillance interval. In 2012, the European Society 
for Gastrointestinal Endoscopy (ESGE) recommended 
that patients with IM or GA at both antrum and 
corpus should be offered surveillance every 3 years[51]. 
For patients with isolated IM in the antrum, regular 
surveillance is not recommended. Figure 1 summarizes 
the management approach recommended by ESGE. 
It remains to be proven whether this approach is 
also applicable to Asia where GC is prevalent. In 
fact, screening of GC is widely practiced in Japan 
and Korea[52] but there is no national guideline on 
surveillance of gastric IM. In a recent survey from 
Korea, it was shown that 95% of specialists perform 
annual endoscopic surveillance for IM[53]. 
Since AG and IM are not uniformly distributed 
in the stomach, proper mapping of the stomach 
with biopsies taken from both antrum (including 
incisura) and corpus are necessary for comprehensive 
assessment of the extent of the lesions. It remains 
to be determined whether further classification of 
IM into different subtypes would have more clinical 
implications on surveillance strategy. It is however 
prudent to treat extensive IM and incomplete IM 
cautiously since the risk of progression to GC appears 
to be higher than patients with focal IM in the antrum 
only. Further studies are needed to determine the 
optimal surveillance strategy for patients with different 
severities of gastric pre-neoplastic lesions, in a manner 
similar to what we are practicing for surveillance of 
different colonic adenoma[54]. 
Although endoscopic surveillance is recommended 
by the ESGE, the way how it is performed remains 
uncertain. Unlike colonoscopy performed for colorectal 
adenoma detection, there is no reliable quality 
indicator for gastroscopic examination. Routine white 
light endoscopy with multiple biopsies taken from the 
antrum and corpus to map the extent of the disease 
appears to be the standard approach. A recent study 
from Singapore showed that endoscopic examination 
times of longer than 7 min identified a greater 
number of high-risk gastric lesions including cancer, 
dysplasia, IM and AG than examinations shorter than 
7 min[55]. There was a 2-fold difference in the detection 
rate of high-risk lesions among slow endoscopists 
regardless of their seniority. Despite the wide use 
of chromoendoscopy in Japan for gastric cancer 
screening, this is not widely practiced in other countries 
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Table 3  Pharmacological treatment of gastric intestinal metaplasia
Ref. Intervention Study design Countries Number of patients Results
Kong et al[38], 
2014 
H. pylori 
eradication
Meta-analysis of 16 trials 
(including 1 RCT and 15 
observational studies)
China, Japan, 
Italy and 
Columbia
3432 Antral IM: pooled WMD with 95%CI: 0.23 (0.18-0.29)
Corpus IM: pooled WMD with 95%CI: -0.01 (-0.04-0.02)
Leung et al[42], 
2006 
Rofecoxib for 
24 mo
RCT (vs placebo) China 213 after H. pylori 
eradication
Antrum IM regression: 24.5% vs 26.9% in placebo
Corpus IM regression 4.3% vs 2.2% in placebo
Wong et al[43],
2012 
Celecoxib for 
24 mo
RCT (H. pylori eradication, 
celecoxib or both)
China 1024 H. pylori 
positive
OR for regression of gastric lesions 1.72 (95%CI: 
1.07-2.76)
You et al[44], 
2006 
Vitamins or 
Anti-oxidants
RCT (H. pylori eradication, 
vitamins or garlic 
supplements)
China 3365 Both vitamins and garlic supplements have no effect 
on gastric precancerous lesion
H. pylori: Helicobacter pylori; RCT: Randomized controlled trial; WMD: Weighted mean difference.
Liu KSH et al . Treatment and surveillance of IM
due to various issues including examination time and 
cost. A recent meta-analysis comparing the diagnostic 
efficacy of white light endoscopy or magnifying 
endoscopy with narrow band imaging showed that 
the latter had a higher diagnostic sensitivity than 
conventional white light endoscopy[56]. Further 
support of the use of image-enhanced endoscopy was 
published from the recent Kyoto Global Consensus 
Conference[57]. In the consensus report, experts 
recognized the shortfall of random biopsies using 
conventional endoscopy and suggested that image-
enhanced endoscopy including chromoendoscopy, 
high-resolution magnification endoscopy and image-
enhanced endoscopy combined with magnification to 
increase the yield from biopsies. Nonetheless, there 
is a need to define in future studies or guidelines the 
appropriate endoscopic modality for surveillance of 
these gastric pre-neoplastic lesions.  
Over the last decade, there are increasing research 
on the relationship between genetic alterations and 
GC development. A number of genes whose functional 
effects range from inflammation to signal transduction 
and cell cycle regulation had been identified[58]. 
For the studies that examined H. pylori and pre-
neoplastic changes, they generally showed positive 
association with the frequency of the specific genetic 
polymorphism with increased severity of changes 
in gastric mucosa. One particular genome wide 
association study by Maran et al[59] showed specific 
single nucleotide polymorphisms (SNPs), namely 
UFM1, THBS4, CYP2C19 and MGST1 genes, were 
associated with AG, complete IM, incomplete IM and 
dysplasia, respectively. This may provide an indirect 
method on surveillance of pre-neoplastic changes and 
avoid the sampling error from random gastric biopsies. 
Unfortunately, the genetic polymorphisms association 
may only be applicable to certain ethnic group. 
Therefore, the findings of these SNPs changes with 
different degree of pre-neoplastic changes need to be 
validated in a different cohort of patients before it can 
be applied globally.
Another less invasive and simple strategy for 
surveillance of gastric pre-neoplastic lesions is the 
use of serum pepsinogen (PG) levels. PGI is secreted 
by chief and mucous neck cells in the corpus and 
fundic glands, whereas PGⅡ is secreted by these cells 
as well as cells in the pyloric glands and Brunner’s 
glands. Hence, any reduction in PGI levels is strongly 
associated with corpus atrophy. Unlike endoscopic 
examination that is invasive and skill dependent, 
measurement of serum PG levels is non-invasive 
and mass population screening is also possible. In 
Japanese series, a low serum PGI or a PGI/Ⅱ ratio 
is a reliable marker for predicting risk of GC[60]. The 
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Figure 1  Flow chart for the management of patients with pre-neoplastic conditions. Modified from Dinis-Ribeiro et al[51].
Patients with atrophic gastritis +/- intestinal metaplasia without dysplasia
H. pylori  eradication if positive
Assess extension of lesions with white light endoscopy (+/- image-enhanced endoscopy such as chromoendoscopy, high-
resolution magnification endoscopy and image-enhanced endoscopy combined with magnification)
At least 4 random biopsies from stomach (2 from antrum and 2 from corpus; both lesser and greater curvature) and 
targeted biopsies from suspicious area
Mild/moderate atrophic gastritis or 
intestinal metaplasia only in antrum
No surveillance endoscopy required
 Intestinal metaplasia both in antrum and corpus 
(equivalent to multifocal atrophic gastritis)
Surveillance endoscopy every 3 years
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use of serum PG screening was also found to be more 
effective than endoscopic screening in a recent cost-
effective analysis[61]. 
Further non-invasive testing of pre-neoplastic 
gastric lesions and GC via exhaled breath is being 
investigated. Amal et al[62] demonstrated that by 
applying nanoarray analysis on the exhaled volatile 
organic compounds could accurately differentiate 
normal gastric mucosa, pre-neoplastic gastric lesions 
(based on OLGIM staging system) and GC. The 
results were encouraging and could be used as a 
future screening and surveillance tool for gastric pre-
neoplastic lesions.
COsT effeCTIveNess aNalysIs 
Of H. pylori eRaDICaTION aND 
sURveIllaNCe Of pRe-NeOplasTIC 
CONDITIONs fOR gC pReveNTION
Cost-effectiveness analysis with the use of math-
ematical model is the mainstream method for 
economic evaluation in health technology assessment 
in recent decades[63]. This method is particularly 
useful to policy makers for making decisions related 
to healthcare intervention assessment and resource 
allocations in view of increased healthcare costs 
and limited budget. Such model is able to simulate 
disease evolution (i.e., provide insights into those 
uncertain aspects of the natural history of the disease 
concerned), present a comprehensive epidemiologic 
model by means of model-based estimates and to 
improve the basis for projecting the future course 
of the disease burden. Under such mathematical 
framework, multiple and diverse data sources on costs, 
clinical effects, and health-related issues concerning 
the effects of alternative strategies on one’s quality 
of life are synthesized to estimate intermediate and 
long-term clinical outcomes. This serves as one of the 
valuable tools to extend the time horizon of existing 
clinical trials to assess public health policies than in 
a single trial, and to evaluate incremental costs and 
effectiveness of alternative strategies to reduce disease 
burden[64]. Although primary preventive strategies 
such as eradicating H. pylori infection have been 
shown in both Caucasian and Asian populations[65-70] to 
be cost-effective by using the mathematical modeling 
approach with a population screening scenario, special 
attention must be paid for the secondary prevention 
which focuses on surveillance of precancerous lesions 
in preventing GC. With the huge variations in the GC 
incidence, prevalence of H. pylori infection and pre-
neoplastic lesions as well as the cost of screening, the 
results may not be applicable to all countries. A recent 
systematic review summarized that there was no 
consistent evidence on cost-effectiveness of endoscopic 
surveillance for premalignant gastric conditions[51,71]. 
Hassan et al[72] study concluded that yearly endoscopy 
surveillance was not cost-effective compared to 
non-surveillance policy in American patients with 
IM [incremental cost-effectiveness ratio (ICER) of 
US$72519 per life-year gained]. Similarly, Yeh et 
al[73] work demonstrated that endoscopic surveillance 
of less advanced lesions (for IM) did not appear to 
be cost-effective (ICER of US$544500 per quality-
adjusted life-year (QALY) for endoscopic mucosal 
resection with surveillance every 10 years) for a cohort 
of US men with a recent incidental diagnosis of gastric 
precancerous lesions (AG, IM or dysplasia), except 
possibly for immigrants from high risk countries. 
Conversely, Areia et al[74] study suggested that 
endoscopic surveillance every 3 years of patients with 
premalignant conditions was cost-effective compared 
to no surveillance in a Portuguese population (ICER 
of Euro$18336 per QALY). The inconsistent results 
might be likely due to different parameter estimates 
on progression rates (e.g., rates from IM to dysplasia, 
from dysplasia to gastric cancer) and costing data 
(e.g., endoscopy) being used[51]. There is also no cost-
effectiveness analysis study conducted in high-risk 
population such as Chinese. More research on cost-
effectiveness of endoscopic surveillance in IM patients 
and high-risk groups are warranted.
CONClUsION
H. pylori is one of the most important causes of GC as 
well as pre-neoplastic gastric lesions. Eradication of H. 
pylori appears to be the best approach in preventing 
the development and subsequent progression of 
gastric pre-neoplastic lesions. Treatment of H. pylori 
should ideally be given at an early stage prior to the 
development of gastric pre-neoplastic lesions to have 
the best long-term outcome, but encouraging results 
are still seen in more recent data of subgroup analysis 
of older patients with advanced gastric lesions. On the 
other hand, the role of endoscopic surveillance of these 
advanced gastric lesions remain uncertain. Universal 
surveillance is unlikely to be helpful, particularly in 
low risk population. A selected group of patients at 
high risk of GC development as identified by proper 
mapping and staging of gastric histology by OLGA or 
OLGIM would be the likely sustainable surveillance 
strategy. More clinical data is desperately needed to 
characterize the best screening tool as well as the 
optimal surveillance interval for patients with gastric 
pre-neoplastic lesions.
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